Compare IMMR & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMMR | XGN |
|---|---|---|
| Founded | 1993 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 229.4M | 253.9M |
| IPO Year | 1999 | 2019 |
| Metric | IMMR | XGN |
|---|---|---|
| Price | $6.44 | $6.43 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $12.25 | ★ $13.67 |
| AVG Volume (30 Days) | ★ 689.7K | 246.3K |
| Earning Date | 12-19-2025 | 11-04-2025 |
| Dividend Yield | ★ 4.65% | N/A |
| EPS Growth | ★ 57.07 | N/A |
| EPS | ★ 2.04 | N/A |
| Revenue | ★ $163,133,000.00 | $63,599,000.00 |
| Revenue This Year | $988.71 | $22.15 |
| Revenue Next Year | $109.72 | $15.26 |
| P/E Ratio | $3.16 | ★ N/A |
| Revenue Growth | ★ 338.21 | 14.08 |
| 52 Week Low | $5.65 | $2.67 |
| 52 Week High | $9.37 | $12.23 |
| Indicator | IMMR | XGN |
|---|---|---|
| Relative Strength Index (RSI) | 42.03 | 24.04 |
| Support Level | $6.42 | $6.37 |
| Resistance Level | $7.09 | $7.29 |
| Average True Range (ATR) | 0.19 | 0.34 |
| MACD | -0.04 | 0.03 |
| Stochastic Oscillator | 6.16 | 1.63 |
Immersion Corp is focused on the creation, design, development, and licensing of haptic technologies that allow people to use its sense of touch more fully as it involves engaging with products and experience the digital world. The company's software focuses on applications in mobile devices, wearables, consumer, and gaming devices markets. It generates revenue from royalty and license fees, and development contract and service fees. Geographically, the company generates a majority of its revenue from Japan, followed by Korea, Germany, United States of America and other countries.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.